Medication info
Candelowon Tablet 20/32 mg (Rosuvastatin, Candesartan)

Candelowon Tablet 20/32 mg (Rosuvastatin, Candesartan)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP X 3)]
Approval status
Active

MFDS item code 202008718 · Approved 2020.12.11 · Insurance code 657808190

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Child dose
○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • risk factors for coronary artery disease
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who require simultaneous administration of Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is used in patients with essential hypertension and heart failure (especially those with impaired left ventricular function) when combination therapy with ACE inhibitors is needed or is not tolerated well. Rosuvastatin is used as an adjunct therapy for uncontrolled hypercholesterolemia, particularly familial hypercholesterolemia and mixed hyperlipidemia, and is also used in the treatment of homozygous familial hypercholesterolemia. Furthermore, it lowers total cholesterol and LDL cholesterol to delay the progression of atherosclerosis and helps reduce the risks of stroke, myocardial infarction, and vascular reintervention in patients at high risk for cardiovascular diseases. This medication is used to effectively manage these cardiovascular diseases and lipid disorders.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Child dose

○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus, especially in the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to this medication, severe liver disease, pregnant or breastfeeding women, patients with severe liver impairment, or those with myopathy should not take this medication. Elderly patients, those with renal insufficiency, and patients with hyperkalemia require special caution when taking this medication, and liver function or muscle condition should be checked regularly. If symptoms such as muscle pain or weakness occur, consultation with a physician should be sought immediately, and blood tests may be needed to check for muscle damage. This medication may affect liver function, so liver enzyme levels should be checked periodically, and if any abnormalities in liver function appear, usage should be discontinued. Inform your doctor of this medication when taking other blood pressure medications, diuretics, certain antibiotics, antifungals, etc., due to the increased risk of side effects from interactions. Women planning pregnancy or who may be pregnant should use appropriate contraceptive methods, and breastfeeding women should either avoid taking this medication or discontinue breastfeeding. Dizziness or fatigue may occur during treatment, so caution should be exercised when driving or operating machinery. In case of overdose, symptoms such as decreased blood pressure, dizziness, and tachycardia may appear, requiring immediate medical attention and treatment. This medication is not recommended for children as its safety and efficacy have not been established in this age group. Keep this medication out of the reach of children and do not transfer it to other containers.

Side effects

Headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, indigestion, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, dizziness, postural dizziness, chalazion, periodontitis, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, nausea, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, angioedema, thrombocytopenia, jaundice, hepatitis, impaired liver function, hematuria, rash, urticaria, itching, angioedema, myalgia, weakness, increased creatine kinase, elevated myoglobin in blood and urine, rhabdomyolysis, arthralgia, low back pain, renal impairment, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorders, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste disturbances, erectile dysfunction, constipation, abdominal pain, pancreatitis, anxiety, depression, somnolence, dyspnea, increased sweating, thrombocytopenia, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnestic syndrome, memory impairment, confusion

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. The recommended storage temperature is between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.